All News
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow
Abstract #L02
💊Phase 3, randomized, placebo-controlled study
💉Biologic naive patients
✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi)
📍benefits sustained to week 52
🛑No new safety signals
Catherine Sims, MD DrCassySims ( View Tweet)
Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful.
@RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
Julian Segan JulianSegan ( View Tweet)
PJP occurs in pts w/ AAV who undergo treatment w/ CYC or RTX, but PJP PPX assoc'd w/ inc incidence of medication-related adverse events. Abs 1081 #ACR22 @RheumNow https://t.co/7vMgx7eMAP https://t.co/bhKPtJBMAO
Dr. Rachel Tate uptoTate ( View Tweet)
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
From my colleague @aili_yoyo. Mimics of vasculitis picked up on imaging. "Isolated abdominal vasculitis" is a surprisingly common consult. Can be tricky sometimes.
@RheumNow #ACR22 #mimics https://t.co/QfeaTHHzdA
Julian Segan JulianSegan ( View Tweet)
Rheumatic Masqueraders: Mimics of Rheumatic Diseases
Mimics of Vasculitis by
- Demographics
- Vascular Distribution
-**Imaging
- Labs
- Clinical Presentation
#ACR22 @RheumNow https://t.co/o0pZoiMqI2
Akhil Sood MD AkhilSoodMD ( View Tweet)
FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression.
@RheumNow ABST1393 #ACR22
https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj
Julian Segan JulianSegan ( View Tweet)
Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI
Richard Conway RichardPAConway ( View Tweet)
Fascinating Abs 0653 #ACR22 In vitro models show JAKis counteract celluar cytotoxicity of HCQ in a human retinal pigment epithelial cell line and podocytes. Possible new way to dec. retinopathy/nephropathy? @RheumNow
https://t.co/5NtLoDzjKG https://t.co/GG2R03xAes
Dr. Rachel Tate uptoTate ( View Tweet)
BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV
Dr. Rachel Tate uptoTate ( View Tweet)
What delays diagnosis of AS? #ACR22 @RheumNow
Abstract #0328
Diagnosed faster if:
👨🦳Older age at back pain onset
🧬HLA-B27+
✋🦶peripheral arthritis
📍Higher socioeconomic vulnerability had diagnostic delay
👁 uveitis more common in patients with > 4 years dx delay
Catherine Sims, MD DrCassySims ( View Tweet)
Inverse association between average yearly HCQ dose and CV damage in cohort of SLE pts from Abs 0982 #ACR22 @RheumNow https://t.co/sfB6ONgwOa https://t.co/FAUGAVe2mB
Dr. Rachel Tate uptoTate ( View Tweet)
Curtis et al @RADoctor . IL6i more effective than conventional immunomodulators in refractory PMR. More likely to discontinue GC (HR 1.32), minimal GC (<2mg) (HR 1.30). @RheumNow #ACR22 Abstr#1547 https://t.co/uzSzrLQ9cB https://t.co/G4pEkOgYm2
Richard Conway RichardPAConway ( View Tweet)
Alle et al. ITP develops into SLE 5.6/1000py. 5.4% of ITP in this study developed SLE after 1801.4py follow up. Assoc refractory ITP, low complement, cytopenias, LA, hypergamma, high titre ANA. @RheumNow #ACR22 Abstr#1455 https://t.co/ORTeB0Q9Pi https://t.co/AVo97uMbpW
Richard Conway RichardPAConway ( View Tweet)
Nice RS3PE irAE description from CanRIO
Two of my RS3PE irAE pts: both severe Sx
one in 2018: not enough PNL until palliation & suffered until then
one in 2022: prompt diagnosis, right PNL dose, living v well now
Hopefully we always continue to improve
ASBT0758 #ACR22 @RheumNow https://t.co/5Ps2HRllNC
David Liew drdavidliew ( View Tweet)
A diagnostic delay of 6 months of #psoriaticarthritis was assoc w/
⬆️incidence of depression
⬆️limitation in participation of social roles & activities
⬆️impact on QoL
in this study by George Gondo @NPF & team
🔖Take home msg: Early dx of PsA is key!
#ACR22 @RheumNow ABST1507 https://t.co/wIZT4MKV4b
sheila RHEUMarampa ( View Tweet)
TMP-SMX PPX dispensed to less than a quarter of GPA pts at the time of RTX. Recent GC had the greatest association w/ PPX. Do you prescribe PPX for your GPA pts #Rheumtwitter? Abs 1071 #ACR22 @RheumNow https://t.co/qJyuGATtJo https://t.co/w4UaGgjEW1
Dr. Rachel Tate uptoTate ( View Tweet)
Shall we cycle TNFi in AxSpA?
CorEvitas registry 86 pts
70% TNFi monotherapy, 23% NSAIDs, 42% high & 24% v high DA
Cycling to 2nd line TNFi
At 6 months: very low achievement of ASDAS-LDA (15%), MCID in ASDAS (7%) & no MI.
https://t.co/S9vnz5PXuX
Abs#1499 #ACR22 @Rheumnow https://t.co/1IZIYcPCBz
Aurelie Najm AurelieRheumo ( View Tweet)
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
Richard Conway RichardPAConway ( View Tweet)